Several past studies have shown that the main hallmark of AD is the loss of irreplaceable nerve cells in the brain, resulting in empty spaces called plaques...Dr. Chen and his team report that the reason why previous clinical trials have failed is that probably the drugs were only targeted at minimizing plaque production and not at controlling downstream reactions such as excessive GABA release triggered by plaque formation